Geneva, Switzerland, 11th January 2010: PregLem SA is pleased to announce that Dr Ernest Loumaye, its CEO and founder, will give a presentation of the company’s business at the 28th J.P. Morgan Healthcare Conference, to be held at the Westin St. Francis Hotel in San Francisco at 11:00 a.m. (PST) on Thursday, 14thJanuary 2010.
The presentation will provide an insight into the company’s therapeutic focus and product market, its business model, the development status of its lead products (PGL4001 and PGL2001), and its business strategy.
About PregLem
PregLem is a Swiss speciality biopharmaceutical company, dedicated to the development and commercialization of a new class of drugs for women’s reproductive health conditions. PregLem has an experienced senior management team, with a proven track record in developing, registering and commercializing reproductive health products. The company is backed by a blue chip investor base.
PregLem in-licensed ulipristal acetate from HRA Pharma to develop it for the treatment of uterine myoma (fibroids) in doses of 5 and 10 mg. HRA recently obtained a positive CHMP recommendation for approval of ulipristal acetate in emergency contraception, a significant step towards de-risking the registration of PregLem’s PGL4001 (see March 2009 press releases on www.hra.comand www.preglem.com).
